HydroCision names Tranchemontagne as CEO | Personnel Moves – March 12, 2019

HydroCision CEO Tranchemontagne

HydroCision said early this month that it tapped former Smith & Nephew (NYSE:SNN) exec Alain Tranchemontagne as its new chief executive officer.

Prior to joining Boston-based HydroCision, Tranchemontagne held a position as U.S. business commercial development senior VP at Smith & Nephew. Before joining Smith & Nephew, Tranchemontagne also held positions at Covidien in senior marketing roles in the patient care division.

We are delighted to have Alain spearhead the next growth chapter in HydroCision’s future. The board was impressed with Alain’s proven track record at major medical device companies, his leadership and market development experience, as well as his passion and energy to broaden the use of our patented, proprietary technology,” board chair John Schulte said in a press release.

“I’m incredibly honored to be joining HydroCision, and I look forward to working closely with the dedicated HydroCision employees and the Board to deliver on the enormous opportunity that lies ahead. I’m also eager to quickly accelerate HydroCision’s growth trajectory, particularly leveraging our unique and differentiated technology into new surgical applications,” Tranchemontagne said in a prepared statement.

 Senseonics taps Kaufman as chief medical officer

Senseonics (NYSE:SENS) said this month it named Dr. Francine Kaufman as its new chief medical officer, effective immediately.

Kaufman previously served as a director at the Comprehensive Childhood Diabetes Center and head of the Children’s Hospital of Los Angeles’ Center for Endocrinology, Diabetes and Metabolism, Germantown, Md.-based Senseonics said.

“We are pleased to have Fran join the executive leadership team at Senseonics. As chief medical officer, she will be instrumental in helping drive forward our innovation platform and the clinical value proposition of the Eversense system. Fran is one of the world’s leading endocrinologists and her deep understanding of the global medical, research, and clinical diabetes community coupled with her track record of applying novel technologies to advance diabetes care for patients make her ideally suited for the role. We are confident that with her leadership, we will further transform and elevate the Eversense platform and bolster our US commercialization efforts at this critical point,” prez & CEO Tim Goodnow said in a press release.

“I am very excited to join the Senseonics team, especially at this point where I feel I have an opportunity to help lay the foundation for the first long-term implantable continuous glucose monitoring system. I have spent my career exploring the treatment and management of diabetes to improve outcomes for patients. I believe in the clinical value the Eversense system provides and am eager to help patients and providers realize its benefits,” Kaufman said in a prepared statement.

Read more

 Camber Spine Tech appoints Dickinson as sales & new biz dev VP

Camber Spine Technologies said last week that it appointed Ryan Dickinson as its new sales and new business dev VP.

Prior to joining King of Prussia, Penn.-based Camber Spine, Dickinson has held positions with Verticor Spine and Invictus Medical, which he helped found.

“After leaving corporate America in 2017 and moving to West Palm Beach I vowed never to return to it again. It only took a few interactions with the founders of Camber Spine to see that they had something truly special brewing. Once I saw the efficacy and revolutionary technology of their implants I was hooked. That coupled with the testimonials of my own doctors using their products, I wanted in, I needed to be a part of what they were doing.  There’s a sense of magic in their implants, a magic that is going to catapult them to limitless heights. I am very excited to join the Camber Spine team. I believe the potential for growth is tremendous given the smart and passionate people that I have already met in the company and a very strong brand portfolio including their two very exciting proprietary technology platforms Spira and Enza,” Dickinson said in a prepared statement.

Read more

 Qure.ai taps former GE Health exec Singh as CCO

Qure.ai said last week that it named former GE Healthcare exec Chiranjiv Singh as its new chief commercial officer.

Prior to joining Qure.ai, Singh served in a number of marketing and sales roles with GE Healthcare including X-ray division chief marketing officer, the San Mateo, Calif.-based company said.

“Chiranjiv’s track record of delivering growth in diverse geographies combined with his recent experience of leveraging the power of artificial intelligence to deliver improved patient outcomes, is aligned to Qure.ai’s key objectives. Over the last 3 years, we have been on a mission to deploy our solutions in the emerging markets, including a strong focus on Tuberculosis, the leading infectious cause of mortality worldwide. Chiranjiv’s global experience will help us reach new markets and drive adoption globally,” co-founcer & CEO Prashant Warier said in a press release.

“I’m proud to join a team that has recently published its 5th peer reviewed journal publication in the last year, including the first AI publication in The Lancet. The data science teams from Qure.ai have also presented more than 20 scientific abstracts at leading Radiology conferences such as RSNA and ECR. While there are many companies building algorithms, the fact that we are one of the few AI healthcare companies that is backing up the technology with both academic and industry validations is proof of the quality of our solutions. I see a huge opportunity for market creation and growth by understanding clinical needs and embedding Qure.ai solutions into user workflows to deliver maximum impact. I’m excited to be part of this journey to deliver value to patients and our healthcare system,” Singh said in a prepared statement.

Read more

 Aethlon Medical names Boswell as quality systems, regulatory affairs director

Aethlon Medical (NSDQ:AEMD) said last week that it appointed Lisa Boswell as its quality systems and regulatory affairs director.

Prior to joining San Diego-based Aethlon Medical, Boswell held positions in quality assurance and regulatory affairs at Zoll Data Systems as well as positions in quality control at GlobeImmune.

“Lisa’s leadership will be critical as we move the Hemopurifier through the next stages of development.  Given the recent designation of the Hemopurifier as a Breakthrough Device by the FDA, it is extremely important that robust Quality Systems and Manufacturing processes are in place to support ongoing development and planned clinical trials,” interim CEO Dr. Timothy Rodell said in a press release.

Read more

The post HydroCision names Tranchemontagne as CEO | Personnel Moves – March 12, 2019 appeared first on MassDevice.

Gerresheimer taps Metzner as CFO | Personnel Moves – December 14, 2018

Gerresheimer CFO Metzner

Gerresheimer said late last month that it tapped Dr. Bernd Metzner as its new chief financial officer, set to take position at the latest by July 1 next year.

Prior to joining the Dusseldorf-based company, Metzner acted as CFO at Ströer, a position he took up in June 2014. He also held positions at Bayer from 2002 to 2011, holding the CFO position for Bayer Italy and the global CFO position for Bayer’s pharma division.

“In Dr. Bernd Metzner, we have gained a highly experienced chief financial officer for Gerresheimer AG. Along with chief executive officer Dietmar Siemssen and management board member Dr. Lukas Burkhardt, Gerresheimer is led by a strong team who will extend the company’s growth trajectory on a lasting basis,” supervisory board chair Dr. Axel Herberg said in a prepared statement.

“Pharma and cosmetics are highly promising, attractive markets. Gerresheimer is a strong global partner to both of these industries. I look forward to being able to bring my experience to bear at Gerresheimer going forward,” Metzner said in a press release.

 Organovo’s Samsara Sciences CSO & prez Presnell steps away

Organovo (PINK:ONVO) said late last month that its subsidiary Samsara Sciences’ chief scientific officer and president Dr. Sharon Presnell is stepping away from their position.

The move went into effect on December 5, the San Diego, Calif.-based company said in an SEC filing.

The move comes as Dr. Presnell looks to relocate to the east coast to “pursue an opportunity with a non-profit foundation and to be closer to family,” Organovo said.

Read more

 GI Dynamics adds Carter as CFO

GI Dynamics (ASX:GID) said on Tuesday that it named Charles Carter as its new chief financial officer.

In addition to his position as CFO, Carter will also serve as the Boston-based company’s treasurer and will replace Dave Bruce as its secretary. Carter has nearly 16 years of experience as a finance exec in the medical industry, GI Dynamics added.

“I am excited to join the GI Dynamics management team at this exciting time in the company’s development. It is clear that this company is committed to serving the large and rapidly growing population of patients with type 2 diabetes and obesity with an innovative treatment option that is clearly needed,” Carter said in a press release.

“On behalf of the GI Dynamics board of directors, I am pleased to announce the appointment of Mr. Carter. We have been working with Mr. Carter for several months now on a more limited basis, and we now look forward to the impact of his expanded leadership role at GI Dynamics as we prepare for the commencement of the GID 18-1 pivotal trial in the U.S. and the EndoBarrier clinical trial in India,” prez & CEO Scott Schorer said in prepared remarks.

Read more

 Amazon, Berkshire Hathaway & JP Morgan HC venture picks up BCBS’s Safran

The healthcare joint venture started by Amazon (NSDQ:AMZN), Berkshire Hathaway and J.P. Morgan has picked up well-known health insurance exec Dana Gelb Safran as its new head of measurement, according to a CNBC report.

Prior to joining the still unnamed venture, Safran served as chief performance measurement and improvement officer at Blue Cross Blue Shield of Massachusetts, according to the report.

Safran is slated to begin their role with the company next year, CNBC said.

Read more

 Aethlon appoints Rodell as interim CEO

Aethlon Medical (NSDQ:AEMD) said yesterday it named Dr. Timothy Rodell as its new interim CEO, effective December 10, succeeding James Joyce who will stay on as a consultant during the transition.

Prior to joining Aethlon, Rodell served as prez & CEO of GlobeImmune, San Diego-based Aethlon said.

“We are delighted to welcome Tim to Aethlon. Tim’s depth and breadth of experience in financing, structuring corporate deals, clinical development and regulatory strategy, both in the U.S. and internationally, will be of great value as we prepare Aethlon for the next phase of development. On behalf of the board of directors, I want to thank Jim Joyce for his leadership, commitment and accomplishments as chief executive officer.  We wish him continued success in his future endeavors,” board chair Dr. Charles Fisher, Jr. said in a press release.

“I am both honored and thrilled to join Aethlon at this time. I believe the Aethlon Hemopurifier has great potential for treating life-threatening viral infections and potentially cancer.  I look forward to working with the team at Aethlon and its collaborators to continue to advance the science and in an effort to bring important treatments to patients and create value for shareholders,” Dr. Rodell said in a prepared statement.

Read more

The post Gerresheimer taps Metzner as CFO | Personnel Moves – December 14, 2018 appeared first on MassDevice.